



26 Broadway
New York, NY 10004
(410) 423-0600 or (800) 533-
CURE
www.jdrf.org



Mission

JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.

Strategy/Approach

JDRF-funded research encompasses T1D at every life stage: stopping or slowing its progression in people who are newly diagnosed, reversing it in those who have lived with the disease for years, avoiding or reversing complications, and preventing the disease in people at risk and in future generations.

JDRF Centers bring together projects linked by a central theme with the aim of testing a clinical outcome during the life of the center. They unite researchers from diverse but relevant fields to develop innovative approaches for treatment and prevention. Currently, JDRF supports nine Beta Cell Therapies Centers, nine Immune Therapies Centers, two Complications Therapies Centers, and one Glucose Control Center.

In addition to research funding and leadership, JDRF's advocacy efforts help support a variety of issues that are critical to achieving its research objectives – such as increased government funding for T1D research and a regulatory environment that allows people with T1D to benefit from potential new therapies and devices as quickly and safely as possible.

Research Portfolio

JDRF research works across three key T1D categories:

- **Cure** – Restore and maintain normal pancreas function
- **Treat** – Improve blood glucose control and resist and reverse complications
- **Prevent** – Develop preventive vaccines and immune therapies

Grant mechanisms include beta cell therapies, immune therapies, prevention therapies, complications therapies, and glucose control along with:

- **Innovative Grants** – Support proposals for highly innovative research with potential to change the current paradigm and/or lead to a seminal discovery.

- *\$110,000/year for one year*
- **Strategic Research Agreements (Single Project, Multi-Project, and Clinical)** – Designed to provide research funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in T1D research.
 - *Funding on a per-application basis*
- **Industry Discovery & Development (IDD) Partnerships** – Intended to provide support to companies/for-profit entities for research programs that are closely focused on a priority area within JDRF's mission.
 - *Up to \$250,000/year for two years for Discovery Partnerships; “As Approved” for Development Partnerships*
- **High Priority, Short-Term Bridge Awards** – Supports research grant applications that address high-priority research areas but failed to receive funding.
 - *\$55,000/year for one year*
- **Conference Grants** – JDRF supports scientific meetings, conferences, and workshops relevant to its mission.
 - *As approved*
- **Training Awards** – Postdoctoral Fellowships, Advanced Postdoctoral Fellowships, Career Development Awards, and Early-Career Patient-Oriented Diabetes Research Awards.
 - *Varies by award: \$43,000 to \$150,000 over three to five years*

The **JDRF Type 1 Diabetes Clinical Trials Connection** helps people with T1D find trials that may be of interest to them or to their family members.

Partnership Practices

JDRF engages in corporate, academic, and nonprofit alliances. One example is the JDRF/Wellcome Trust Diabetes and Inflammation Laboratory centered in the Cambridge Institute for Medical Research.

JDRF is focused on establishing partnerships with both pharmaceutical and biotechnology companies to accelerate the discovery, development, and commercialization of disease-modifying therapeutics and devices to better treat and cure type 1 diabetes and its complications. JDRF's industry partnership structure can support programs or entire companies, public or private, that are aligned with its core research and strategic therapeutic objectives. Partners include Novartis, Pfizer, Sanofi, Amylin, Eli Lilly, Genzyme, Tolterx, Genentech, and Biogen Idec.

Financials

JDRF is a 501(c)(3) tax-exempt corporation. More than 80 percent of JDRF's expenditures directly support research and research-related education. The latest financial information available is from FY2013.¹

Year Ending 6/30/13:

- Revenue: \$206,223,491
- Assets: \$196,040,120
- Grants: \$106,005,315
- Expenditures: \$209,495,741

Key Accomplishments

- JDRF provided more than \$110 million for T1D research in 2012 and currently has research projects in 17 countries, totaling \$530 million.
- Since its founding in 1970, JDRF has awarded more than \$1.6 billion to T1D research, including \$116 million in FY2011.
- In 2012, JDRF supported more than 50 clinical studies, including evaluations of new therapies.
- Through funding and support, JDRF moved the artificial pancreas from concept to human trials, forging new regulatory pathways. FDA released draft artificial pancreas guidance in December 2011 – just nine months after JDRF proposal.
- Time Magazine called JDRF "one of the nation's most forceful disease advocacy groups."
- JDRF's Children's Congress brings more than 150 children with T1D and their families to Washington every other year to educate policymakers on the critical need for research funds.

Leadership

JDRF is governed by an international **Board of Directors** and managed by a New York-based **leadership staff**.

- **President and CEO:** Jeffrey Brewer, jbrewer@jdrf.org
- **VP of Development Strategy and Planning:** John McGuire, CFRE, jmcguire@jdrf.org
- **Chief Science Officer:** Richard Insel, MD, rinsel@jdrf.org
- **VP of Advocacy & Policy:** Cynthia Rice
- **Director of Industry Partnerships:** Peter Lomedico

¹ Information obtained from Foundation Center Directory, <http://fconline.foundationcenter.org>, June 2013.